![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
CRBP Corbus Pharmaceuticals
- 8.5100
- -0.9700-10.23%
Close Feb 14 16:00 ET
- 8.5100
- 0.00000.00%
Post 19:57 ET
103.65MMarket Cap-1.81P/E (TTM)
9.4100High8.0100Low1.16MVolume8.2700Open9.4800Pre Close10.07MTurnover14.98%Turnover RatioLossP/E (Static)12.18MShares61.900052wk High0.69P/B66.02MFloat Cap8.010052wk Low--Dividend TTM7.76MShs Float323.4000Historical High--Div YieldTTM14.77%Amplitude2.1100Historical Low8.6590Avg Price1Lot Size
Corbus Pharmaceuticals Stock Forum
Sign in to post a comment
$Corbus Pharmaceuticals (CRBP.US)$
The Phase 1 clinical trial results for CRB-701 represent a significant advancement in the antibody-drug conjugate (ADC) space, particularly in addressing the historical challenges of ADC toxicity profiles. The observed 4% combined rate of peripheral neuropathy across both Western and Chinese studies is notably lower than existing ADC treatments, where rates can exceed 30-50% with current standard-of-care options.
The drug's differentiat...
The Phase 1 clinical trial results for CRB-701 represent a significant advancement in the antibody-drug conjugate (ADC) space, particularly in addressing the historical challenges of ADC toxicity profiles. The observed 4% combined rate of peripheral neuropathy across both Western and Chinese studies is notably lower than existing ADC treatments, where rates can exceed 30-50% with current standard-of-care options.
The drug's differentiat...
2
1
$Corbus Pharmaceuticals (CRBP.US)$
Breakthrough Cancer Drug CRB-701 Delivers Powerful Results in Phase 1 Trial: Multiple Tumor Types Respond
Breakthrough Cancer Drug CRB-701 Delivers Powerful Results in Phase 1 Trial: Multiple Tumor Types Respond
$Corbus Pharmaceuticals (CRBP.US)$
Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets
Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets
1
$Corbus Pharmaceuticals (CRBP.US)$ wtf bought at 18.50 and now 14.9 🥲🥹🙏
$Corbus Pharmaceuticals (CRBP.US)$
wow drop 62%. 😲
wow drop 62%. 😲
1
1
Got in at $16, this is gonna be a pretty long hold for me, wanna see how it plays out
5
3
Hello Mooers! ![]()
A quick recap for the month ending April 30, 2024.
![]()
Ten stocks with >300% YTD
![]()
$Swvl Holdings (SWVL.US)$718.40%
![]()
$Root Inc (ROOT.US)$564.60%
![]()
$Elevation Oncology (ELEV.US)$561.08%
![]()
$JanOne (JAN.US)$554.05%
![]()
$GeneDx Holdings (WGS.US)$520.71%
![]()
$Corbus Pharmaceuticals (CRBP.US)$513.25%
![]()
$AGBA Group (AGBA.US)$482.90%
![]()
$Janux Therapeutics (JANX.US)$431.22%
![]()
$Dave Inc (DAVE.US)$4...
A quick recap for the month ending April 30, 2024.
4
1
1
No comment yet
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
J L 7 2 : Now even good news is of no use, the stock price is plummeting
.